Have a feature idea you'd love to see implemented?
Let us know!
CRVO CervoMed Inc
Price (delayed)
$9.58
Market cap
$79.07M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.18
Enterprise value
$71.33M
diffusion pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. the company is developing
Highlights
The revenue has soared by 116% YoY and by 4.3% QoQ
CervoMed's gross profit has soared by 116% YoY and by 4.3% from the previous quarter
CervoMed's EPS has shrunk by 122% QoQ but it has surged by 64% YoY
CRVO's net income has shrunk by 137% QoQ
The company's equity fell by 9% QoQ
Key stats
What are the main financial stats of CRVO
Market
Valuations
Earnings
Shares outstanding
8.25M
Market cap
$79.07M
Enterprise value
$71.33M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.73
Price to sales (P/S)
8.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.09
Revenue
$10.07M
EBIT
-$11.95M
EBITDA
-$11.95M
Free cash flow
-$11.02M
Per share
Balance sheet
Liquidity
EPS
-$2.18
Free cash flow per share
-$1.27
Book value per share
$5.53
Revenue per share
$1.16
TBVPS
$5.62
Total assets
$48.88M
Total liabilities
$3.25M
Debt
$0
Equity
$45.64M
Working capital
$45.56M
Debt to equity
0
Current ratio
15.04
Quick ratio
14.45
Net debt/EBITDA
0.65
Margins
Efficiency
Dividend
EBITDA margin
-118.7%
Gross margin
100%
Net margin
-118.7%
Operating margin
-133.8%
Return on assets
-39.8%
Return on equity
-44.1%
Return on invested capital
-62.5%
Return on capital employed
-26.2%
Return on sales
-118.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRVO stock price
How has the CervoMed stock price performed over time
Intraday
-0.62%
1 week
-12.27%
1 month
-27.31%
1 year
-2.24%
YTD
25.56%
QTD
-34.38%
Financial performance
How have CervoMed's revenue and profit performed over time
Revenue
$10.07M
Gross profit
$10.07M
Operating income
-$13.47M
Net income
-$11.95M
Gross margin
100%
Net margin
-118.7%
CRVO's net income has shrunk by 137% QoQ
The net margin has plunged by 127% from the previous quarter
The revenue has soared by 116% YoY and by 4.3% QoQ
CervoMed's gross profit has soared by 116% YoY and by 4.3% from the previous quarter
Growth
What is CervoMed's growth rate over time
Valuation
What is CervoMed stock price valuation
P/E
N/A
P/B
1.73
P/S
8.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.09
CervoMed's EPS has shrunk by 122% QoQ but it has surged by 64% YoY
The P/B is 82% below the last 4 quarters average of 9.6 and 38% below the 5-year quarterly average of 2.8
The company's equity fell by 9% QoQ
The revenue has soared by 116% YoY and by 4.3% QoQ
The stock's price to sales (P/S) is 32% less than its last 4 quarters average of 12.2
Efficiency
How efficient is CervoMed business performance
CervoMed's return on sales has shrunk by 127% QoQ
The ROA has plunged by 64% from the previous quarter
The return on equity has dropped by 58% since the previous quarter but it has increased by 44% year-on-year
The company's return on invested capital fell by 17% QoQ
Dividends
What is CRVO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRVO.
Financial health
How did CervoMed financials performed over time
The total liabilities has grown by 32% YoY
The company's total assets fell by 8% QoQ
The debt is 100% less than the equity
The company's equity fell by 9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.